Global Pharmacogenomics Technology (Theranostics & CDx) Market Growth (Status and Outlook) 2022-2028


Mar, 2022 | Report ID: 227495 | 165 | Pharmaceuticals and Healthcare

As the global economy mends, the 2021 growth of Pharmacogenomics Technology (Theranostics & CDx) will have significant change from previous year. According to our latest study, the global Pharmacogenomics Technology (Theranostics & CDx) market size is USD million in 2022 from USD 9383.3 million in 2021, with a change of % between 2021 and 2022. The global Pharmacogenomics Technology (Theranostics & CDx) market size will reach USD 25340 million in 2028, growing at a CAGR of 15.2% over the analysis period.

The United States Pharmacogenomics Technology (Theranostics & CDx) market is expected at value of US$ million in 2021 and grow at approximately % CAGR during review period. China constitutes a % market for the global Pharmacogenomics Technology (Theranostics & CDx) market, reaching US$ million by the year 2028. As for the Europe Pharmacogenomics Technology (Theranostics & CDx) landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period. In APAC, the growth rates of other notable markets (Japan and South Korea) are projected to be at % and % respectively for the next 5-year period.

Global main Pharmacogenomics Technology (Theranostics & CDx) players cover Illumina, Roche, Agilent, and Abbott, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.

This report presents a comprehensive overview, market shares, and growth opportunities of Pharmacogenomics Technology (Theranostics & CDx) market by product type, application, key players and key regions and countries.

Segmentation by type: breakdown data from 2017 to 2022 in Section 2.3; and forecast to 2028 in section 10.7.

Instrument

Reagents and Consumables

Others

Segmentation by application: breakdown data from 2017 to 2022, in Section 2.4; and forecast to 2028 in section 10.8.

Tumor

Diabetes

Mental Diseases

Cardiovascular Diseases

Others

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major players in the market. The key players covered in this report: Breakdown data in in Chapter 3.

Illumina

Roche

Agilent

Abbott

Thermofisher

Qiagen

Guardant Health

MGI Tech Co., Ltd.

Amoydx Biology

Genomics


Frequently Asked Questions

The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.

Market is segmented on the basis:

  • By Type
  • By Application
  • By Region
  • By Country
  • By Manufacturer

The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.

The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.

1 Scope of the Report

1.1 Market Introduction

1.2 Years Considered

1.3 Research Objectives

1.4 Market Research Methodology

1.5 Research Process and Data Source

1.6 Economic Indicators

1.7 Currency Considered

2 Executive Summary

2.1 World Market Overview

2.1.1 Global Pharmacogenomics Technology (Theranostics & CDx) Market Size 2017-2028

2.1.2 Pharmacogenomics Technology (Theranostics & CDx) Market Size CAGR by Region 2017 VS 2022 VS 2028

2.2 Pharmacogenomics Technology (Theranostics & CDx) Segment by Type

2.2.1 Instrument

2.2.2 Reagents and Consumables

2.2.3 Others

2.3 Pharmacogenomics Technology (Theranostics & CDx) Market Size by Type

2.3.1 Pharmacogenomics Technology (Theranostics & CDx) Market Size CAGR by Type (2017 VS 2022 VS 2028)

2.3.2 Global Pharmacogenomics Technology (Theranostics & CDx) Market Size Market Share by Type (2017-2022)

2.4 Pharmacogenomics Technology (Theranostics & CDx) Segment by Application

2.4.1 Tumor

2.4.2 Diabetes

2.4.3 Mental Diseases

2.4.4 Cardiovascular Diseases

2.4.5 Others

2.5 Pharmacogenomics Technology (Theranostics & CDx) Market Size by Application

2.5.1 Pharmacogenomics Technology (Theranostics & CDx) Market Size CAGR by Application (2017 VS 2022 VS 2028)

2.5.2 Global Pharmacogenomics Technology (Theranostics & CDx) Market Size Market Share by Application (2017-2022)

3 Pharmacogenomics Technology (Theranostics & CDx) Market Size by Player

3.1 Pharmacogenomics Technology (Theranostics & CDx) Market Size Market Share by Players

3.1.1 Global Pharmacogenomics Technology (Theranostics & CDx) Revenue by Players (2020-2022)

3.1.2 Global Pharmacogenomics Technology (Theranostics & CDx) Revenue Market Share by Players (2020-2022)

3.2 Global Pharmacogenomics Technology (Theranostics & CDx) Key Players Head office and Products Offered

3.3 Market Concentration Rate Analysis

3.3.1 Competition Landscape Analysis

3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)

3.4 New Products and Potential Entrants

3.5 Mergers & Acquisitions, Expansion

4 Pharmacogenomics Technology (Theranostics & CDx) by Regions

4.1 Pharmacogenomics Technology (Theranostics & CDx) Market Size by Regions (2017-2022)

4.2 Americas Pharmacogenomics Technology (Theranostics & CDx) Market Size Growth (2017-2022)

4.3 APAC Pharmacogenomics Technology (Theranostics & CDx) Market Size Growth (2017-2022)

4.4 Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size Growth (2017-2022)

4.5 Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size Growth (2017-2022)

5 Americas

5.1 Americas Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2017-2022)

5.2 Americas Pharmacogenomics Technology (Theranostics & CDx) Market Size by Type (2017-2022)

5.3 Americas Pharmacogenomics Technology (Theranostics & CDx) Market Size by Application (2017-2022)

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Pharmacogenomics Technology (Theranostics & CDx) Market Size by Region (2017-2022)

6.2 APAC Pharmacogenomics Technology (Theranostics & CDx) Market Size by Type (2017-2022)

6.3 APAC Pharmacogenomics Technology (Theranostics & CDx) Market Size by Application (2017-2022)

6.4 China

6.5 Japan

6.6 Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

7 Europe

7.1 Europe Pharmacogenomics Technology (Theranostics & CDx) by Country (2017-2022)

7.2 Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size by Type (2017-2022)

7.3 Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size by Application (2017-2022)

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 Middle East & Africa

8.1 Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) by Region (2017-2022)

8.2 Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size by Type (2017-2022)

8.3 Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size by Application (2017-2022)

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 Market Drivers, Challenges and Trends

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 Global Pharmacogenomics Technology (Theranostics & CDx) Market Forecast

10.1 Global Pharmacogenomics Technology (Theranostics & CDx) Forecast by Regions (2023-2028)

10.1.1 Global Pharmacogenomics Technology (Theranostics & CDx) Forecast by Regions (2023-2028)

10.1.2 Americas Pharmacogenomics Technology (Theranostics & CDx) Forecast

10.1.3 APAC Pharmacogenomics Technology (Theranostics & CDx) Forecast

10.1.4 Europe Pharmacogenomics Technology (Theranostics & CDx) Forecast

10.1.5 Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Forecast

10.2 Americas Pharmacogenomics Technology (Theranostics & CDx) Forecast by Country (2023-2028)

10.2.1 United States Pharmacogenomics Technology (Theranostics & CDx) Market Forecast

10.2.2 Canada Pharmacogenomics Technology (Theranostics & CDx) Market Forecast

10.2.3 Mexico Pharmacogenomics Technology (Theranostics & CDx) Market Forecast

10.2.4 Brazil Pharmacogenomics Technology (Theranostics & CDx) Market Forecast

10.3 APAC Pharmacogenomics Technology (Theranostics & CDx) Forecast by Region (2023-2028)

10.3.1 China Pharmacogenomics Technology (Theranostics & CDx) Market Forecast

10.3.2 Japan Pharmacogenomics Technology (Theranostics & CDx) Market Forecast

10.3.3 Korea Pharmacogenomics Technology (Theranostics & CDx) Market Forecast

10.3.4 Southeast Asia Pharmacogenomics Technology (Theranostics & CDx) Market Forecast

10.3.5 India Pharmacogenomics Technology (Theranostics & CDx) Market Forecast

10.3.6 Australia Pharmacogenomics Technology (Theranostics & CDx) Market Forecast

10.4 Europe Pharmacogenomics Technology (Theranostics & CDx) Forecast by Country (2023-2028)

10.4.1 Germany Pharmacogenomics Technology (Theranostics & CDx) Market Forecast

10.4.2 France Pharmacogenomics Technology (Theranostics & CDx) Market Forecast

10.4.3 UK Pharmacogenomics Technology (Theranostics & CDx) Market Forecast

10.4.4 Italy Pharmacogenomics Technology (Theranostics & CDx) Market Forecast

10.4.5 Russia Pharmacogenomics Technology (Theranostics & CDx) Market Forecast

10.5 Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Forecast by Region (2023-2028)

10.5.1 Egypt Pharmacogenomics Technology (Theranostics & CDx) Market Forecast

10.5.2 South Africa Pharmacogenomics Technology (Theranostics & CDx) Market Forecast

10.5.3 Israel Pharmacogenomics Technology (Theranostics & CDx) Market Forecast

10.5.4 Turkey Pharmacogenomics Technology (Theranostics & CDx) Market Forecast

10.5.5 GCC Countries Pharmacogenomics Technology (Theranostics & CDx) Market Forecast

10.6 Global Pharmacogenomics Technology (Theranostics & CDx) Forecast by Type (2023-2028)

10.7 Global Pharmacogenomics Technology (Theranostics & CDx) Forecast by Application (2023-2028)

11 Key Players Analysis

11.1 Illumina

11.1.1 Illumina Company Information

11.1.2 Illumina Pharmacogenomics Technology (Theranostics & CDx) Product Offered

11.1.3 Illumina Pharmacogenomics Technology (Theranostics & CDx) Revenue, Gross Margin and Market Share (2020-2022)

11.1.4 Illumina Main Business Overview

11.1.5 Illumina Latest Developments

11.2 Roche

11.2.1 Roche Company Information

11.2.2 Roche Pharmacogenomics Technology (Theranostics & CDx) Product Offered

11.2.3 Roche Pharmacogenomics Technology (Theranostics & CDx) Revenue, Gross Margin and Market Share (2020-2022)

11.2.4 Roche Main Business Overview

11.2.5 Roche Latest Developments

11.3 Agilent

11.3.1 Agilent Company Information

11.3.2 Agilent Pharmacogenomics Technology (Theranostics & CDx) Product Offered

11.3.3 Agilent Pharmacogenomics Technology (Theranostics & CDx) Revenue, Gross Margin and Market Share (2020-2022)

11.3.4 Agilent Main Business Overview

11.3.5 Agilent Latest Developments

11.4 Abbott

11.4.1 Abbott Company Information

11.4.2 Abbott Pharmacogenomics Technology (Theranostics & CDx) Product Offered

11.4.3 Abbott Pharmacogenomics Technology (Theranostics & CDx) Revenue, Gross Margin and Market Share (2020-2022)

11.4.4 Abbott Main Business Overview

11.4.5 Abbott Latest Developments

11.5 Thermofisher

11.5.1 Thermofisher Company Information

11.5.2 Thermofisher Pharmacogenomics Technology (Theranostics & CDx) Product Offered

11.5.3 Thermofisher Pharmacogenomics Technology (Theranostics & CDx) Revenue, Gross Margin and Market Share (2020-2022)

11.5.4 Thermofisher Main Business Overview

11.5.5 Thermofisher Latest Developments

11.6 Qiagen

11.6.1 Qiagen Company Information

11.6.2 Qiagen Pharmacogenomics Technology (Theranostics & CDx) Product Offered

11.6.3 Qiagen Pharmacogenomics Technology (Theranostics & CDx) Revenue, Gross Margin and Market Share (2020-2022)

11.6.4 Qiagen Main Business Overview

11.6.5 Qiagen Latest Developments

11.7 Guardant Health

11.7.1 Guardant Health Company Information

11.7.2 Guardant Health Pharmacogenomics Technology (Theranostics & CDx) Product Offered

11.7.3 Guardant Health Pharmacogenomics Technology (Theranostics & CDx) Revenue, Gross Margin and Market Share (2020-2022)

11.7.4 Guardant Health Main Business Overview

11.7.5 Guardant Health Latest Developments

11.8 MGI Tech Co., Ltd.

11.8.1 MGI Tech Co., Ltd. Company Information

11.8.2 MGI Tech Co., Ltd. Pharmacogenomics Technology (Theranostics & CDx) Product Offered

11.8.3 MGI Tech Co., Ltd. Pharmacogenomics Technology (Theranostics & CDx) Revenue, Gross Margin and Market Share (2020-2022)

11.8.4 MGI Tech Co., Ltd. Main Business Overview

11.8.5 MGI Tech Co., Ltd. Latest Developments

11.9 Amoydx Biology

11.9.1 Amoydx Biology Company Information

11.9.2 Amoydx Biology Pharmacogenomics Technology (Theranostics & CDx) Product Offered

11.9.3 Amoydx Biology Pharmacogenomics Technology (Theranostics & CDx) Revenue, Gross Margin and Market Share (2020-2022)

11.9.4 Amoydx Biology Main Business Overview

11.9.5 Amoydx Biology Latest Developments

11.10 Genomics

11.10.1 Genomics Company Information

11.10.2 Genomics Pharmacogenomics Technology (Theranostics & CDx) Product Offered

11.10.3 Genomics Pharmacogenomics Technology (Theranostics & CDx) Revenue, Gross Margin and Market Share (2020-2022)

11.10.4 Genomics Main Business Overview

11.10.5 Genomics Latest Developments

12 Research Findings and Conclusion

List of Tables

Table 1. Pharmacogenomics Technology (Theranostics & CDx) Market Size CAGR by Region (2017 VS 2022 VS 2028) & ($ Millions)

Table 2. Major Players of Instrument

Table 3. Major Players of Reagents and Consumables

Table 4. Major Players of Others

Table 5. Pharmacogenomics Technology (Theranostics & CDx) Market Size CAGR by Type (2017 VS 2022 VS 2028) & ($ Millions)

Table 6. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size by Type (2017-2022) & ($ Millions)

Table 7. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size Market Share by Type (2017-2022)

Table 8. Pharmacogenomics Technology (Theranostics & CDx) Market Size CAGR by Application (2017 VS 2022 VS 2028) & ($ Millions)

Table 9. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size by Application (2017-2022) & ($ Millions)

Table 10. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size Market Share by Application (2017-2022)

Table 11. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue by Players (2020-2022) & ($ Millions)

Table 12. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue Market Share by Player (2020-2022)

Table 13. Pharmacogenomics Technology (Theranostics & CDx) Key Players Head office and Products Offered

Table 14. Pharmacogenomics Technology (Theranostics & CDx) Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)

Table 15. New Products and Potential Entrants

Table 16. Mergers & Acquisitions, Expansion

Table 17. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size by Regions 2017-2022 & ($ Millions)

Table 18. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size Market Share by Regions (2017-2022)

Table 19. Americas Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2017-2022) & ($ Millions)

Table 20. Americas Pharmacogenomics Technology (Theranostics & CDx) Market Size Market Share by Country (2017-2022)

Table 21. Americas Pharmacogenomics Technology (Theranostics & CDx) Market Size by Type (2017-2022) & ($ Millions)

Table 22. Americas Pharmacogenomics Technology (Theranostics & CDx) Market Size Market Share by Type (2017-2022)

Table 23. Americas Pharmacogenomics Technology (Theranostics & CDx) Market Size by Application (2017-2022) & ($ Millions)

Table 24. Americas Pharmacogenomics Technology (Theranostics & CDx) Market Size Market Share by Application (2017-2022)

Table 25. APAC Pharmacogenomics Technology (Theranostics & CDx) Market Size by Region (2017-2022) & ($ Millions)

Table 26. APAC Pharmacogenomics Technology (Theranostics & CDx) Market Size Market Share by Region (2017-2022)

Table 27. APAC Pharmacogenomics Technology (Theranostics & CDx) Market Size by Type (2017-2022) & ($ Millions)

Table 28. APAC Pharmacogenomics Technology (Theranostics & CDx) Market Size Market Share by Type (2017-2022)

Table 29. APAC Pharmacogenomics Technology (Theranostics & CDx) Market Size by Application (2017-2022) & ($ Millions)

Table 30. APAC Pharmacogenomics Technology (Theranostics & CDx) Market Size Market Share by Application (2017-2022)

Table 31. Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2017-2022) & ($ Millions)

Table 32. Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size Market Share by Country (2017-2022)

Table 33. Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size by Type (2017-2022) & ($ Millions)

Table 34. Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size Market Share by Type (2017-2022)

Table 35. Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size by Application (2017-2022) & ($ Millions)

Table 36. Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size Market Share by Application (2017-2022)

Table 37. Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size by Region (2017-2022) & ($ Millions)

Table 38. Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size Market Share by Region (2017-2022)

Table 39. Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size by Type (2017-2022) & ($ Millions)

Table 40. Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size Market Share by Type (2017-2022)

Table 41. Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size by Application (2017-2022) & ($ Millions)

Table 42. Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size Market Share by Application (2017-2022)

Table 43. Key Market Drivers & Growth Opportunities of Pharmacogenomics Technology (Theranostics & CDx)

Table 44. Key Market Challenges & Risks of Pharmacogenomics Technology (Theranostics & CDx)

Table 45. Key Industry Trends of Pharmacogenomics Technology (Theranostics & CDx)

Table 46. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size Forecast by Regions (2023-2028) & ($ Millions)

Table 47. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size Market Share Forecast by Regions (2023-2028)

Table 48. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size Forecast by Type (2023-2028) & ($ Millions)

Table 49. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size Market Share Forecast by Type (2023-2028)

Table 50. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size Forecast by Application (2023-2028) & ($ Millions)

Table 51. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size Market Share Forecast by Application (2023-2028)

Table 52. Illumina Details, Company Type, Pharmacogenomics Technology (Theranostics & CDx) Area Served and Its Competitors

Table 53. Illumina Pharmacogenomics Technology (Theranostics & CDx) Product Offered

Table 54. Illumina Pharmacogenomics Technology (Theranostics & CDx) Revenue ($ million), Gross Margin and Market Share (2020-2022)

Table 55. Illumina Main Business

Table 56. Illumina Latest Developments

Table 57. Roche Details, Company Type, Pharmacogenomics Technology (Theranostics & CDx) Area Served and Its Competitors

Table 58. Roche Pharmacogenomics Technology (Theranostics & CDx) Product Offered

Table 59. Roche Main Business

Table 60. Roche Pharmacogenomics Technology (Theranostics & CDx) Revenue ($ million), Gross Margin and Market Share (2020-2022)

Table 61. Roche Latest Developments

Table 62. Agilent Details, Company Type, Pharmacogenomics Technology (Theranostics & CDx) Area Served and Its Competitors

Table 63. Agilent Pharmacogenomics Technology (Theranostics & CDx) Product Offered

Table 64. Agilent Main Business

Table 65. Agilent Pharmacogenomics Technology (Theranostics & CDx) Revenue ($ million), Gross Margin and Market Share (2020-2022)

Table 66. Agilent Latest Developments

Table 67. Abbott Details, Company Type, Pharmacogenomics Technology (Theranostics & CDx) Area Served and Its Competitors

Table 68. Abbott Pharmacogenomics Technology (Theranostics & CDx) Product Offered

Table 69. Abbott Main Business

Table 70. Abbott Pharmacogenomics Technology (Theranostics & CDx) Revenue ($ million), Gross Margin and Market Share (2020-2022)

Table 71. Abbott Latest Developments

Table 72. Thermofisher Details, Company Type, Pharmacogenomics Technology (Theranostics & CDx) Area Served and Its Competitors

Table 73. Thermofisher Pharmacogenomics Technology (Theranostics & CDx) Product Offered

Table 74. Thermofisher Main Business

Table 75. Thermofisher Pharmacogenomics Technology (Theranostics & CDx) Revenue ($ million), Gross Margin and Market Share (2020-2022)

Table 76. Thermofisher Latest Developments

Table 77. Qiagen Details, Company Type, Pharmacogenomics Technology (Theranostics & CDx) Area Served and Its Competitors

Table 78. Qiagen Pharmacogenomics Technology (Theranostics & CDx) Product Offered

Table 79. Qiagen Main Business

Table 80. Qiagen Pharmacogenomics Technology (Theranostics & CDx) Revenue ($ million), Gross Margin and Market Share (2020-2022)

Table 81. Qiagen Latest Developments

Table 82. Guardant Health Details, Company Type, Pharmacogenomics Technology (Theranostics & CDx) Area Served and Its Competitors

Table 83. Guardant Health Pharmacogenomics Technology (Theranostics & CDx) Product Offered

Table 84. Guardant Health Main Business

Table 85. Guardant Health Pharmacogenomics Technology (Theranostics & CDx) Revenue ($ million), Gross Margin and Market Share (2020-2022)

Table 86. Guardant Health Latest Developments

Table 87. MGI Tech Co., Ltd. Details, Company Type, Pharmacogenomics Technology (Theranostics & CDx) Area Served and Its Competitors

Table 88. MGI Tech Co., Ltd. Pharmacogenomics Technology (Theranostics & CDx) Product Offered

Table 89. MGI Tech Co., Ltd. Main Business

Table 90. MGI Tech Co., Ltd. Pharmacogenomics Technology (Theranostics & CDx) Revenue ($ million), Gross Margin and Market Share (2020-2022)

Table 91. MGI Tech Co., Ltd. Latest Developments

Table 92. Amoydx Biology Details, Company Type, Pharmacogenomics Technology (Theranostics & CDx) Area Served and Its Competitors

Table 93. Amoydx Biology Pharmacogenomics Technology (Theranostics & CDx) Product Offered

Table 94. Amoydx Biology Main Business

Table 95. Amoydx Biology Pharmacogenomics Technology (Theranostics & CDx) Revenue ($ million), Gross Margin and Market Share (2020-2022)

Table 96. Amoydx Biology Latest Developments

Table 97. Genomics Details, Company Type, Pharmacogenomics Technology (Theranostics & CDx) Area Served and Its Competitors

Table 98. Genomics Pharmacogenomics Technology (Theranostics & CDx) Product Offered

Table 99. Genomics Main Business

Table 100. Genomics Pharmacogenomics Technology (Theranostics & CDx) Revenue ($ million), Gross Margin and Market Share (2020-2022)

Table 101. Genomics Latest Developments

List of Figures

Figure 1. Pharmacogenomics Technology (Theranostics & CDx) Report Years Considered

Figure 2. Research Objectives

Figure 3. Research Methodology

Figure 4. Research Process and Data Source

Figure 5. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size Growth Rate 2017-2028 ($ Millions)

Figure 6. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size Market Share by Type in 2021

Figure 7. Pharmacogenomics Technology (Theranostics & CDx) in Tumor

Figure 8. Global Pharmacogenomics Technology (Theranostics & CDx) Market: Tumor (2017-2022) & ($ Millions)

Figure 9. Pharmacogenomics Technology (Theranostics & CDx) in Diabetes

Figure 10. Global Pharmacogenomics Technology (Theranostics & CDx) Market: Diabetes (2017-2022) & ($ Millions)

Figure 11. Pharmacogenomics Technology (Theranostics & CDx) in Mental Diseases

Figure 12. Global Pharmacogenomics Technology (Theranostics & CDx) Market: Mental Diseases (2017-2022) & ($ Millions)

Figure 13. Pharmacogenomics Technology (Theranostics & CDx) in Cardiovascular Diseases

Figure 14. Global Pharmacogenomics Technology (Theranostics & CDx) Market: Cardiovascular Diseases (2017-2022) & ($ Millions)

Figure 15. Pharmacogenomics Technology (Theranostics & CDx) in Others

Figure 16. Global Pharmacogenomics Technology (Theranostics & CDx) Market: Others (2017-2022) & ($ Millions)

Figure 17. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size Market Share by Application in 2021

Figure 18. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue Market Share by Player in 2021

Figure 19. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size Market Share by Regions (2017-2022)

Figure 20. Americas Pharmacogenomics Technology (Theranostics & CDx) Market Size 2017-2022 ($ Millions)

Figure 21. APAC Pharmacogenomics Technology (Theranostics & CDx) Market Size 2017-2022 ($ Millions)

Figure 22. Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size 2017-2022 ($ Millions)

Figure 23. Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size 2017-2022 ($ Millions)

Figure 24. Americas Pharmacogenomics Technology (Theranostics & CDx) Value Market Share by Country in 2021

Figure 25. Americas Pharmacogenomics Technology (Theranostics & CDx) Consumption Market Share by Type in 2021

Figure 26. Americas Pharmacogenomics Technology (Theranostics & CDx) Market Size Market Share by Application in 2021

Figure 27. United States Pharmacogenomics Technology (Theranostics & CDx) Market Size Growth 2017-2022 ($ Millions)

Figure 28. Canada Pharmacogenomics Technology (Theranostics & CDx) Market Size Growth 2017-2022 ($ Millions)

Figure 29. Mexico Pharmacogenomics Technology (Theranostics & CDx) Market Size Growth 2017-2022 ($ Millions)

Figure 30. Brazil Pharmacogenomics Technology (Theranostics & CDx) Market Size Growth 2017-2022 ($ Millions)

Figure 31. APAC Pharmacogenomics Technology (Theranostics & CDx) Market Size Market Share by Region in 2021

Figure 32. APAC Pharmacogenomics Technology (Theranostics & CDx) Market Size Market Share by Application in 2021

Figure 33. China Pharmacogenomics Technology (Theranostics & CDx) Market Size Growth 2017-2022 ($ Millions)

Figure 34. Japan Pharmacogenomics Technology (Theranostics & CDx) Market Size Growth 2017-2022 ($ Millions)

Figure 35. Korea Pharmacogenomics Technology (Theranostics & CDx) Market Size Growth 2017-2022 ($ Millions)

Figure 36. Southeast Asia Pharmacogenomics Technology (Theranostics & CDx) Market Size Growth 2017-2022 ($ Millions)

Figure 37. India Pharmacogenomics Technology (Theranostics & CDx) Market Size Growth 2017-2022 ($ Millions)

Figure 38. Australia Pharmacogenomics Technology (Theranostics & CDx) Market Size Growth 2017-2022 ($ Millions)

Figure 39. Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size Market Share by Country in 2021

Figure 40. Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size Market Share by Type in 2021

Figure 41. Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size Market Share by Application in 2021

Figure 42. Germany Pharmacogenomics Technology (Theranostics & CDx) Market Size Growth 2017-2022 ($ Millions)

Figure 43. France Pharmacogenomics Technology (Theranostics & CDx) Market Size Growth 2017-2022 ($ Millions)

Figure 44. UK Pharmacogenomics Technology (Theranostics & CDx) Market Size Growth 2017-2022 ($ Millions)

Figure 45. Italy Pharmacogenomics Technology (Theranostics & CDx) Market Size Growth 2017-2022 ($ Millions)

Figure 46. Russia Pharmacogenomics Technology (Theranostics & CDx) Market Size Growth 2017-2022 ($ Millions)

Figure 47. Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size Market Share by Region in 2021

Figure 48. Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size Market Share by Type in 2021

Figure 49. Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size Market Share by Application in 2021

Figure 50. Egypt Pharmacogenomics Technology (Theranostics & CDx) Market Size Growth 2017-2022 ($ Millions)

Figure 51. South Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size Growth 2017-2022 ($ Millions)

Figure 52. Israel Pharmacogenomics Technology (Theranostics & CDx) Market Size Growth 2017-2022 ($ Millions)

Figure 53. Turkey Pharmacogenomics Technology (Theranostics & CDx) Market Size Growth 2017-2022 ($ Millions)

Figure 54. GCC Country Pharmacogenomics Technology (Theranostics & CDx) Market Size Growth 2017-2022 ($ Millions)

Figure 55. Americas Pharmacogenomics Technology (Theranostics & CDx) Market Size 2023-2028 ($ Millions)

Figure 56. APAC Pharmacogenomics Technology (Theranostics & CDx) Market Size 2023-2028 ($ Millions)

Figure 57. Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size 2023-2028 ($ Millions)

Figure 58. Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size 2023-2028 ($ Millions)

Figure 59. United States Pharmacogenomics Technology (Theranostics & CDx) Market Size 2023-2028 ($ Millions)

Figure 60. Canada Pharmacogenomics Technology (Theranostics & CDx) Market Size 2023-2028 ($ Millions)

Figure 61. Mexico Pharmacogenomics Technology (Theranostics & CDx) Market Size 2023-2028 ($ Millions)

Figure 62. Brazil Pharmacogenomics Technology (Theranostics & CDx) Market Size 2023-2028 ($ Millions)

Figure 63. China Pharmacogenomics Technology (Theranostics & CDx) Market Size 2023-2028 ($ Millions)

Figure 64. Japan Pharmacogenomics Technology (Theranostics & CDx) Market Size 2023-2028 ($ Millions)

Figure 65. Korea Pharmacogenomics Technology (Theranostics & CDx) Market Size 2023-2028 ($ Millions)

Figure 66. Southeast Asia Pharmacogenomics Technology (Theranostics & CDx) Market Size 2023-2028 ($ Millions)

Figure 67. India Pharmacogenomics Technology (Theranostics & CDx) Market Size 2023-2028 ($ Millions)

Figure 68. Australia Pharmacogenomics Technology (Theranostics & CDx) Market Size 2023-2028 ($ Millions)

Figure 69. Germany Pharmacogenomics Technology (Theranostics & CDx) Market Size 2023-2028 ($ Millions)

Figure 70. France Pharmacogenomics Technology (Theranostics & CDx) Market Size 2023-2028 ($ Millions)

Figure 71. UK Pharmacogenomics Technology (Theranostics & CDx) Market Size 2023-2028 ($ Millions)

Figure 72. Italy Pharmacogenomics Technology (Theranostics & CDx) Market Size 2023-2028 ($ Millions)

Figure 73. Russia Pharmacogenomics Technology (Theranostics & CDx) Market Size 2023-2028 ($ Millions)

Figure 74. Spain Pharmacogenomics Technology (Theranostics & CDx) Market Size 2023-2028 ($ Millions)

Figure 75. Egypt Pharmacogenomics Technology (Theranostics & CDx) Market Size 2023-2028 ($ Millions)

Figure 76. South Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size 2023-2028 ($ Millions)

Figure 77. Israel Pharmacogenomics Technology (Theranostics & CDx) Market Size 2023-2028 ($ Millions)

Figure 78. Turkey Pharmacogenomics Technology (Theranostics & CDx) Market Size 2023-2028 ($ Millions)

Figure 79. GCC Countries Pharmacogenomics Technology (Theranostics & CDx) Market Size 2023-2028 ($ Millions)

Sample Request is not available